Diagnosis and management of pertussis
- Protection against pertussis by immunisation. McKendrick, M.W.; Gully, P.R.; Geddes, A.M. // British Medical Journal;11/22/1980, Vol. 281 Issue 6252, p1390
Examines the efficacy of pertussis immunization for the protection against Bordetella pertussis infection. Severity of the illness in infants; Epidemiology of pertussis; Protection against the complication of the disease.
- Neonatal BoÄŸmaca: Vaka Sunumu. Kayiran, Sinan Mahir; Gürakan, Berkan // Journal of the Child / Cocuk Dergisi;Dec2010, Vol. 10 Issue 4, p207
Pertussis is a highly contagious respiratory system infection of Bordetella pertussis which can be prevented with an immunization protocol. Although it can be seen in all age groups, the disease pursues a more severe course resulting in hospital stay and mortality in infants under 6 months and...
- Pertussis vaccination decreased rate of severe infection, illness duration. // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p55
The article discusses a study and an accompanying commentary, published online on March 14, 2014 by "Clinical Infectious Diseases," regarding the lower rate of severe infection and illness duration in children immunized with acellular pertussis vaccine.
- Manifestations of Pertussis in Immunized Children and Adults. Kirchner, Jeffrey T. // American Family Physician;11/1/1999, Vol. 60 Issue 7, p2148
Provides information on the prevalence and incidence of Bordetella pertussis (B. pertussis) infections in adults. Clinical presentation and course of B. pertussis infection among immunized persons; Diagnosis and treatment of B. pertussis infection.
- Whooping cough vaccine `should be replaced'. Brown, Phyllida // New Scientist;10/23/93, Vol. 140 Issue 1896, p7
Reports on the use of acellular vaccines as replacement for whooping cough vaccine or pertussis. Existing whole-cell vaccine based on a suspension of the whole, killed bacterium, Bordetella pertussis; Limitations of the United States Food and Drug Administration-licensed acellular vaccine.
- Reactions after pertussis vaccine: a manufacturer's experiences and difficulties since 1964. Griffith, A.H. // British Medical Journal;4/1/1978, Vol. 1 Issue 6116, p809
Pertussis vaccines vary in quality, safety, and efficacy according to the production strains of Bordetella pertussis, the method of manufacture, and quality control procedures. It is therefore not justifiable to combine information on the incidence, nature, and severity of reactions after all...
- Editorial Commentary: Accounting for Pertussis. DeMaria, Alfred // Clinical Infectious Diseases;Jun2012, Vol. 54 Issue 12, p1736
An introduction is presented in which the editor discusses the article on pertussis vaccines.
- Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children. Vickers, David; Ross, Allen G.; Mainar-Jaime, Raúl C.; Neudorf, Cordell; Shah, Syed // CMAJ: Canadian Medical Association Journal;11/7/2006, Vol. 175 Issue 10, p1213
Background: The transition from a whole-cell to a 5-component acellular pertussis vaccine provided a unique opportunity to compare the effect that each type of vaccine had on the incidence of pertussis, under routine conditions, among children less than 10 years of age. Methods: Analyses were...
- Time since last vaccine dose in PCR-positive and PCR-negative children with suspected pertussis to monitor pertussis vaccine effectiveness. Riffelmann, M.; Mohr, J.; Hellenbrand, W.; Wirsing von Koenig, C. // European Journal of Clinical Microbiology & Infectious Diseases;May2014, Vol. 33 Issue 5, p805
We evaluated whether the results of diagnostic polymerase chain reaction (PCR) testing combined with time since last vaccine dose could be used to monitor the effectiveness of acellular pertussis vaccines. In 258 consecutive nasopharyngeal swabs from children and adolescents with typical...